文献速递糖尿病

恩格列净与其他降糖药对主要不良肾脏事件风险的比较有效性

Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
PubMed 文献 · Diabetes Care · 2020-09-10

这项队列研究纳入379,033例新使用恩格列净或其他非SGLT2i降糖药的2型糖尿病患者,采用倾向评分加权生存分析。结果显示,与其它降糖药相比,恩格列净使eGFR年下降减少0.99 mL/min/1.73 m2,BMI年下降多0.25 kg/m2,并降低主要不良肾脏事件风险(HR 0.68,95%CI 0.64-0.73)。

要点

  • 恩格列净较其他非SGLT2i降糖药显著降低主要不良肾脏事件风险(HR 0.68)。
  • 恩格列净延缓eGFR年下降0.99 mL/min/1.73 m2,并额外降低BMI 0.25 kg/m2。
  • 肾脏获益在各eGFR分层、白蛋白尿分层及有无心血管病人群中一致。

核心结论

  • 在2型糖尿病患者中,与其它非SGLT2i降糖药相比,恩格列净使用与eGFR保留、BMI更大幅度下降及主要不良肾脏事件风险降低相关。

研究设计与样本

  • 队列研究,纳入379,033例新使用恩格列净或其他非SGLT2i降糖药的2型糖尿病患者,使用倾向评分加权生存分析。

主要发现

  • 恩格列净组eGFR年下降较其他降糖药组少0.99(95%CI 0.51-1.55)mL/min/1.73 m2。
  • 恩格列净组BMI年下降较其他降糖药组多0.25(95%CI 0.16-0.33)kg/m2。
  • 恩格列净组主要不良肾脏事件风险降低(HR 0.68,95%CI 0.64-0.73)。
  • 在eGFR≥90、≥60至<90、≥45至<60、≥30至<45 mL/min/1.73 m2亚组中,HR分别为0.70(95%CI 0.60-0.82)、0.66(0.60-0.73)、0.78(0.69-0.89)、0.71(0.55-0.92)。
  • 在无白蛋白尿、微量白蛋白尿和大量白蛋白尿亚组中,HR分别为0.65(95%CI 0.57-0.75)、0.72(0.66-0.79)、0.74(0.62-0.88);在有和无心血管病亚组中,HR分别为0.67(0.61-0.74)和0.76(0.69-0.83)。

临床怎么用

  • 对于2型糖尿病患者,恩格列净可考虑用于延缓eGFR下降和降低主要不良肾脏事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the risk of major adverse kidney events (MAKE) of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease, or all-cause mortality. RESEARCH DESIGN AND METHODS: In a cohort study of 379,033 new users of empagliflozin or other non-SGLT2i antihyperglycemics, predefined variables and covariates identified by a high-dimensional variable selection algorithm were used to build propensity scores. Weighted survival analyses were then applied to estimate the risk of MAKE. RESULTS: Compared with other antihyperglycemics, empagliflozin use was associated with 0.99 (95% CI 0.51, 1.55) mL/min/1.73 m2 less annual reduction in eGFR, 0.25 (95% CI 0.16, 0.33) kg/m2 more annual decrease in BMI, and reduced risk of MAKE (hazard ratio [HR] 0.68 [95% CI 0.64, 0.73]). Empagliflozin use was associated with reduced risk of MAKE in eGFR ≥90, ≥60 to <90, ≥45 to <60, and ≥30 to <45 mL/min/1.73 m2 (HR 0.70 [95% CI 0.60, 0.82], 0.66 [0.60, 0.73], 0.78 [0.69, 0.89]), and 0.71 [0.55, 0.92], respectively), in participants without albuminuria, with microalbuminuria and macroalbuminuria (HR 0.65 [95% CI 0.57, 0.75], 0.72 [0.66. 0.79], and 0.74 [0.62, 0.88], respectively), and in participants with and without cardiovascular disease (HR 0.67 [95% CI 0.61, 0.74] and 0.76 [0.69, 0.83], respectively). The association was evident in per-protocol analyses, which required continuation of the assigned antihyperglycemic medication (empagliflozin or other antihyperglycemics) during follow-up (HR 0.64 [95% CI 0.60, 0.70]), and in analyses requiring concurrent use of metformin in at least the first 90 days of follow-up (HR 0.63 [0.57-0.69]). CONCLUSIONS: Among people with type 2 diabetes, empagliflozin use was associated with eGFR preservation, a greater decline in BMI, and a reduced risk of MAKE compared with other non-SGLT2i antihyperglycemics.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Xie Y, Bowe B, Gibson AK, et al. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care. 2020. PMID: 32912850. doi:10.2337/dc20-1231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。